SAR of a series of inhaled A2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data

被引：24

作者：

Mantell, Simon J. ^{[1
]}

Stephenson, Peter T. ^{[1
]}

Monaghan, Sandra M. ^{[1
]}

Maw, Graham N. ^{[1
]}

Trevethick, Michael A. ^{[1
]}

Yeadon, Michael ^{[1
]}

Walker, Don K. ^{[1
]}

Selby, Matthew D. ^{[1
]}

Batchelor, David V. ^{[1
]}

Rozze, Stuart ^{[1
]}

Chavaroche, Helene ^{[1
]}

Lemaitre, Arnaud ^{[1
]}

Wright, Karen N. ^{[1
]}

Whitlock, Lynsey ^{[1
]}

Stuart, Emilio F. ^{[1
]}

Wright, Patricia A. ^{[1
]}

Macintyre, Fiona ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, Sandwich Labs, Sandwich CT13 9NJ, Kent, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2009年 / 19卷 / 15期

关键词：

A2A; COPD; Pharmacokinetics; Inhalation; OBSTRUCTIVE PULMONARY-DISEASE; RECEPTOR AGONIST; INFLAMMATION; THERAPY;

D O I：

10.1016/j.bmcl.2009.05.027

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

COPD is a major cause of mortality in the western world. A(2A) agonists are postulated to reduce the lung inflammation that causes COPD. The cardiovascular effects of A(2A) agonists dictate that a compound needs to be delivered by inhalation to be therapeutically useful. The pharmacological and pharmacokinetic SAR of a series of inhaled A(2A) agonists is described leading through to human pharmacokinetic data for a clinical candidate. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：4471 / 4475

页数：5

共 50 条

[1] Inhaled adenosine A2A receptor agonists for the treatment of chronic obstructive pulmonary disease
Mantell, Simon J.
Stephenson, Peter T.
Monaghan, Sandra M.
Maw, Graham N.
Trevethick, Michael A.
Yeadon, Michael
Keir, Ruth F.
Walker, Don K.
Jones, Rhys M.
Selby, Matthew D.
Batchelor, David V.
Rozze, Stuart
Chavaroche, Helene
Hobson, Tim J.
Dodd, Peter G.
Lemaitre, Arnaud
Wright, Karen N.
Stuart, Emilio F.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (04) : 1284 - 1287
[2] Clinical concerns with inhaled β2-agonists -: Adult asthma
Cockcroft, D. W.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2006, 31 (2-3) : 197 - 207
[3] Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane
Wissing, H
Kuhn, I
Rietbrock, S
Fuhr, U
BRITISH JOURNAL OF ANAESTHESIA, 2000, 84 (04) : 443 - 449
[4] A Pharmacokinetic/Pharmacodynamic Model of Inhaled Insulin with Application to Clinical Trial Simulation
Marino, Mark T.
DIABETES, 2010, 59 : A552 - A552
[5] A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats
Jones, Rhys M.
Harrison, Anthony
XENOBIOTICA, 2012, 42 (01) : 75 - 85
[6] A PHARMACOKINETIC MODEL OF INHALED METHANOL IN HUMANS AND COMPARISON TO METHANOL DISPOSITION IN MICE AND RATS
PERKINS, RA
WARD, KW
POLLACK, GM
ENVIRONMENTAL HEALTH PERSPECTIVES, 1995, 103 (7-8) : 726 - 733
[7] MODEL FOR TRACHEOBRONCHIAL CLEARANCE OF INHALED PARTICLES IN MAN AND A COMPARISON WITH DATA
LEE, PS
GERRITY, TR
HASS, FJ
LOURENCO, RV
IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 1979, 26 (11) : 624 - 630
[8] Combination of inhaled corticosteroids and beta(2)-agonists in asthma - Clinical and economic implications
RuttenvanMolken, MPMH
Kerstjens, HAM
CLINICAL IMMUNOTHERAPEUTICS, 1996, 6 (06): : 489 - 505
[9] Comparison of the bronchodilating effects of inhaled β2-agonists after methacholine challenge in a human lung reperfusion model
Gnadt, Mirjam
Trammer, Beatrice
Kardziev, Boris
Bayliss, Martin K.
Edwards, Chris D.
Schmidt, Michael
Hoegger, Petra
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 81 (03) : 617 - 626
[10] Comparison of bronchodilatory properties of transdermal and inhaled long-acting β2-agonists
Yamagata, T.
Hirano, T.
Sugiura, H.
Yanagisawa, S.
Ichikawa, T.
Ueshima, K.
Akamatsu, K.
Nakanishi, M.
Matsunaga, K.
Minakata, Y.
Ichinose, M.
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2008, 21 (01) : 160 - 165

← 1 2 3 4 5 →